XML 26 R15.htm IDEA: XBRL DOCUMENT v3.8.0.1
Summary of Significant Accounting Policies (Tables)
 9 Months Ended
Oct. 31, 2017
Accounting Policies [Abstract]  
Fair Value of Liabilities on a Recurring Basis
The table below provides information on our liabilities that are measured at fair value on a recurring basis:
 
Total Fair Value
 
Quoted Prices in Active Markets
(Level 1)
 
Significant Other Observable Inputs
(Level 2)
 
Significant Unobservable Inputs
(Level 3)
At October 31, 2017
 
 
 
 
 
 
 
Warrants liability (1)
$
151,000

 
$
—

 
$
—

 
$
151,000

Royalty liability (2)
2,456,000

 
—

 
—

 
2,456,000

 
 
 
 
 
 
 
 
At January 31, 2017
 
 
 
 
 
 
 
Warrants liability (1)
$
46,000

 
$
—

 
$
—

 
$
46,000

Royalty liability (2)
2,351,000

 
—

 
—

 
2,351,000

 _______________
(1)
The initial fair value of warrants liability was determined by management with the assistance of an independent third-party valuation specialist, and by management thereafter. Changes in fair value of the warrants are recognized within miscellaneous expense in the condensed consolidated statements of operations.
(2)
The initial fair value of royalty liability was determined by management with the assistance of an independent third-party valuation specialist, and by management thereafter. The fair value of the royalty liability is determined based on the probability-weighted revenue scenarios for the Streamline Health® Clinical AnalyticsTM solution (“Clinical Analytics”) licensed from Montefiore Medical Center (discussed in Note 3 - Acquisitions and Divestitures). Fair value adjustments are included within miscellaneous expense in the condensed consolidated statements of operations.
Schedule of Earnings Per Share, Basic and Diluted
The following is the calculation of the basic and diluted net earnings (loss) per share of common stock:
 
Three Months Ended
 
October 31, 2017
 
October 31, 2016
Net earnings (loss)
$
3,489

 
$
(1,930,472
)
Less: deemed dividends on Series A Preferred Stock
—

 
(72,710
)
Net earnings (loss) attributable to common stockholders
$
3,489

 
$
(2,003,182
)
Weighted average shares outstanding used in basic per common share computations
19,985,822

 
19,645,521

Restricted stock and Series A Convertible Preferred Stock
3,082,601

 
—

Number of shares used in diluted per common share computation
23,068,423

 
19,645,521

Basic net earnings (loss) per share of common stock
$
0.00

 
$
(0.10
)
Diluted net earnings (loss) per share of common stock
$
0.00

 
$
(0.10
)
 
Nine Months Ended
 
October 31, 2017
 
October 31, 2016
Net loss
$
(3,137,084
)
 
$
(4,142,381
)
Less: deemed dividends on Series A Preferred Stock
—

 
(875,935
)
Net loss attributable to common stockholders
$
(3,137,084
)
 
$
(5,018,316
)
Weighted average shares outstanding used in basic per common share computations
19,838,691

 
19,477,538

Restricted stock and Series A Convertible Preferred Stock
—

 
—

Number of shares used in diluted per common share computation
19,838,691

 
19,477,538

Basic net loss per share of common stock
$
(0.16
)
 
$
(0.26
)
Diluted net loss per share of common stock
$
(0.16
)
 
$
(0.26
)